DiaMedica Therapeutics Inc.

DMACSEC EDGAR

Pharmaceutical Preparations(Z4)CIK: 1401040

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$13.1M	$7.8M	$8.8M	$8.2M	$7.9M
Operating Expenses	$21.3M	$14.0M	$13.6M	$12.7M	$11.6M
Operating Income (Loss)	-$21.3M	-$14.0M	-$13.6M	-$12.7M	-$11.6M
Nonoperating Income (Expense)	$1.9M	$353.0K	$82.0K	$434.0K	$975.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$19.3M	-$13.6M	-$13.6M	-$12.3M	—
Income Tax Expense (Benefit)	$43.0K	$28.0K	$28.0K	$27.0K	$31.0K
Net Income (Loss) Attributable to Parent	-$19.4M	-$13.7M	-$13.6M	-$12.3M	-$10.6M
Earnings Per Share, Basic	-$0.60	-$0.52	-$0.65	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$54.2M	$34.4M	$45.6M	$28.1M	$9.1M
Assets, Current	$53.7M	$33.8M	$45.4M	$27.9M	$8.8M
Cash and Cash Equivalents, at Carrying Value	$4.5M	$4.7M	$4.7M	$7.4M	$3.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$369.0K	$82.0K	$130.0K	$340.0K	$823.0K
Liabilities, Current	$2.8M	$2.2M	$1.5M	$2.0M	$1.3M
Accounts Payable, Current	$926.0K	$734.0K	$509.0K	$1.1M	$182.0K
Stockholders' Equity Attributable to Parent	$31.8M	$44.0M	$26.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$18.7M	-$11.5M	-$12.3M	-$9.2M	-$9.1M
Net Cash Provided by (Used in) Investing Activities	-$18.3M	$11.5M	-$20.5M	-$16.1M	-$3.9M
Net Cash Provided by (Used in) Financing Activities	$36.8M	-$6.0K	$30.1M	$28.8M	$70.0K
Payments to Acquire Property, Plant, and Equipment	$24.0K	$81.0K	$22.0K	$47.0K	$2.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)